SYDNEY, AUSTRALIA: ZOONO Group Limited (ASX: ZNO), a global biotech company, has announced the appointment of Mr. Barry Woolcott as Group Chief Executive Officer (CEO).

Following an extensive executive search, Mr. Woolcott joined Zoono in September 2021, initially as Global General Manager, with the intention that, at a mutually agreed date, he would assume the role of Chief Executive Officer.

Commenting on the appointment, Managing Director and major shareholder, Mr. Paul Hyslop, said “The Board is delighted to confirm Barry’s appointment as CEO.”

“Since joining the Company, Barry has been focussed on strategy development and project delivery. He is uniquely positioned to understand the challenges and opportunities that face Zoono. Barry has proven leadership capabilities and I look forward to working with him to grow our Company.”

“Our priorities in selecting a new CEO were to identify someone who could lead the Company through a transformational growth phase and guide the Company’s targeted global activities. Equally critical was a demonstrated ability to develop the Company’s capabilities and culture to suit the evolving business environment.”

Mr. Woolcott said he was excited to have the opportunity to lead Zoono. “Zoono is a great company with a fantastic product range and an exciting future. I look forward to working with the management team to transform the way we work as we look to continually improve and evolve.”

Prior to joining Zoono, Mr. Woolcott developed his management capabilities through 7 years at Deloitte and, more recently, 13 years (the last 8 as Group CEO) at Jacobsen Holdings, a privately owned group of New Zealand based companies.

Mr. Woolcott holds a Bachelor of Commerce with Honours from Queens University, Kingston, Ontario and an MBA from Auckland University.

ZOONO Group Limited is a global biotech company that develops, manufactures, and distributes a suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. ZOONO’s mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

ZOONO produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the ‘ZOONO molecule’, a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi, and mould.

ZOONO’s products have received numerous regulatory approvals and ZOONO’s technology claims are supported by independent testing conducted in laboratories worldwide. ZOONO is headquartered in New Zealand and its products are available globally. www.ZOONO.com